News

Reverdia starts its bio-succinic acid plant
Enlarge image

BusinessItalyNetherlandsFrance

Reverdia starts its bio-succinic acid plant

17.12.2012 - Reverdia has started industrial production of bio-succinic acid at a new production plant with an annual capacity of 10,000 metric tons.

The joint venture between Dutch DSM NV and French starch producer Roquette Frères has begun operations in Cassano Spinola, Italy, at a commercial-scale plant producing Biosuccinium™ sustainable succinic acid. The company said the plant, which has a capacity of about 10,000 tonnes/yr, was unique in its kind, being the world’s first dedicated large-scale plant for the production of succinic acid from renewable resources. However, according to US-based BioAmber Inc, which fused BioAmber SAS and US company DNP Green Technology in 2010, it has been producing the chemical building block at 4,000 tonnes/yr since 2009.

Both producers rely on genetically engineered E.coli strains for producing the compound, that is being used to make bioplastics, chemical internmediates such as 1,4 butanediol, solvents, coatings, and phthalate-free plasticisers. As the market for bio-based succinic acid is expected to grow rapidly in the next few years, other joint-ventures such as Succinity or US-based Myriant Inc. are building production facilities. Reverdia will market its bio-succinium in collaboration with Helm.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/reverdia-starts-its-bio-succinic-acid-plant.html

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NORDIC NANOVECTOR (N)31.90 NOK12.72%
  • VITA 34 (D)4.46 EUR5.69%
  • SAREUM HOLDINGS (UK)0.78 GBP5.41%

FLOP

  • MOLOGEN (D)1.80 EUR-6.74%
  • GW PHARMACEUTICALS (UK)518.00 GBP-5.39%
  • DIAXONHIT (F)0.38 EUR-5.00%

TOP

  • DIAMYD MEDICAL -B- (S)7.20 SEK67.4%
  • KARO BIO (S)41.60 SEK33.8%
  • NORDIC NANOVECTOR (N)31.90 NOK30.7%

FLOP

  • BIONOR PHARMA (N)0.44 NOK-27.9%
  • NOVOZYMES (DK)287.30 DKK-13.5%
  • WILEX (D)1.50 EUR-13.3%

TOP

  • NICOX (F)10.18 EUR438.6%
  • SAREUM HOLDINGS (UK)0.78 GBP271.4%
  • GENMAB (DK)1103.00 DKK96.8%

FLOP

  • BB BIOTECH (D)45.05 EUR-82.2%
  • EVOCUTIS (UK)0.04 GBP-80.0%
  • CIRCASSIA LIMITED (L)92.75 GBP-71.5%

No liability assumed, Date: 25.08.2016